CLINICAL_TRIALS
trial_result
· 2019-01-03
Clinical Trial Update: Fulvestrant With or Without Ganetespib in HR+ Breast Cancer [Phase 2]
Summary
Phase 2 study assessing fulvestrant with or without ganetespib in HR-positive breast cancer has completed, with results posted in January 2019.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Dana-Farber Cancer Institute | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2019-01-03